Hypoaldosteronism epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(16 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{Hypoaldosteronism}}
{{Hypoaldosteronism}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}}{{Akshun}}
==Overview==
==Overview==
In hospitalized [[patients]] the [[incidence]] of hypoaldosteronism is 3000 per 100,000 individuals. The [[prevalence]] rate of hypoaldosteronism in United states is estimated to be 200,000 cases. Hypoaldosteronism is most commonly seen in middle-aged and older individuals. Both men and women are affected equally. Hypoaldosteronism is more prevalent in African-American, Native Americans, and Hispanics.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The epidemiology and demographics of hypoaldosteronism is given below:<ref name="pmid22891694">{{cite journal |vauthors=Haas CS, Pohlenz I, Lindner U, Muck PM, Arand J, Suefke S, Lehnert H |title=Renal tubular acidosis type IV in hyperkalaemic patients--a fairy tale or reality? |journal=Clin. Endocrinol. (Oxf) |volume=78 |issue=5 |pages=706–11 |year=2013 |pmid=22891694 |doi=10.1111/j.1365-2265.2012.04446.x |url=}}</ref><ref name="pmid19937982">{{cite journal |vauthors=Raebel MA, Ross C, Cheetham C, Petersen H, Saylor G, Smith DH, Wright LA, Roblin DW, Xu S |title=Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates |journal=Pharmacoepidemiol Drug Saf |volume=19 |issue=1 |pages=19–25 |year=2010 |pmid=19937982 |doi=10.1002/pds.1882 |url=}}</ref><ref name="pmid2220773">{{cite journal |vauthors=Michelis MF |title=Hyperkalemia in the elderly |journal=Am. J. Kidney Dis. |volume=16 |issue=4 |pages=296–9 |year=1990 |pmid=2220773 |doi= |url=}}</ref>
===Incidence===
===Incidence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The [[incidence]] of hypoaldosteronism in hospitalized [[patient]] is approximately 3000 per 100,000 individuals.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
 
===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The [[prevalence]] of hypoaldosteronism is approximately 667 per 100,000 individuals.
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The [[prevalence]] of hypoaldosteronism is estimated to be 200,000 cases in the United States.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
*The case-fatality rate of [disease name] is approximately [number range].
===Age===
===Age===
*Hypoaldosteronism is most commonly seen in middle-aged and older individuals.
*Hypoaldosteronism is most commonly seen in middle-aged and older individuals.
*Elderly patients on multiple drug therapy (polypharmacy) have an increased incidence of drug induced hypoaldosteronism.
*Elderly patients on multiple [[drug]] therapy ([[polypharmacy]]) have an increased [[incidence]] of drug induced hypoaldosteronism.
*In younger patients, hypoaldosteronism is seen in patients with underlying diabetes mellitus type I or sickle cell disease.
*In younger patients, hypoaldosteronism is seen in [[patients]] with underlying [[Diabetes mellitus type 1|diabetes mellitus type I]] or [[sickle cell disease]].


===Race===
===Race===
*There is no racial predilection to [disease name].
*Hypoaldosteronism is more prevalent in African-American, Native Americans, and Hispanics.
*Hypoaldosteronism usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].


===Gender===
===Gender===
*[Disease name] affects men and women equally.
*Hypoaldosteronism affects both men and women equally.
*[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
===Region===
*The majority of [disease name] cases are reported in [geographical region].
 
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===
 
 


==References==
==References==
Line 46: Line 31:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Disease]]
[[Category:Endocrinology]]
[[Category:Nephrology]]
[[Category:Emergency medicine]]
[[Category:Medicine]]
[[Category:Up-To-Date]]

Latest revision as of 16:38, 18 October 2017

Hypoaldosteronism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoaldosteronism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoaldosteronism epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoaldosteronism epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoaldosteronism epidemiology and demographics

CDC on Hypoaldosteronism epidemiology and demographics

Hypoaldosteronism epidemiology and demographics in the news

Blogs on Hypoaldosteronism epidemiology and demographics

Directions to Hospitals Treating Hypoaldosteronism

Risk calculators and risk factors for Hypoaldosteronism epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

In hospitalized patients the incidence of hypoaldosteronism is 3000 per 100,000 individuals. The prevalence rate of hypoaldosteronism in United states is estimated to be 200,000 cases. Hypoaldosteronism is most commonly seen in middle-aged and older individuals. Both men and women are affected equally. Hypoaldosteronism is more prevalent in African-American, Native Americans, and Hispanics.

Epidemiology and Demographics

The epidemiology and demographics of hypoaldosteronism is given below:[1][2][3]

Incidence

  • The incidence of hypoaldosteronism in hospitalized patient is approximately 3000 per 100,000 individuals.

Prevalence

  • The prevalence of hypoaldosteronism is approximately 667 per 100,000 individuals.
  • The prevalence of hypoaldosteronism is estimated to be 200,000 cases in the United States.

Age

Race

  • Hypoaldosteronism is more prevalent in African-American, Native Americans, and Hispanics.

Gender

  • Hypoaldosteronism affects both men and women equally.

References

  1. Haas CS, Pohlenz I, Lindner U, Muck PM, Arand J, Suefke S, Lehnert H (2013). "Renal tubular acidosis type IV in hyperkalaemic patients--a fairy tale or reality?". Clin. Endocrinol. (Oxf). 78 (5): 706–11. doi:10.1111/j.1365-2265.2012.04446.x. PMID 22891694.
  2. Raebel MA, Ross C, Cheetham C, Petersen H, Saylor G, Smith DH, Wright LA, Roblin DW, Xu S (2010). "Increasingly restrictive definitions of hyperkalemia outcomes in a database study: effect on incidence estimates". Pharmacoepidemiol Drug Saf. 19 (1): 19–25. doi:10.1002/pds.1882. PMID 19937982.
  3. Michelis MF (1990). "Hyperkalemia in the elderly". Am. J. Kidney Dis. 16 (4): 296–9. PMID 2220773.

Template:WH Template:WS